Jefferies analyst Tycho Peterson initiated coverage of Caris Life Sciences with a Buy rating and $28 price target. The firm sees \"secular tailwinds\" in the oncology diagnostics space from improving therapies and declining sequencing costs, but also \"ongoing polarization between the leaders and laggards.\" Jefferies views Caris Life Sciences and Veracyte as \"compelling stocks\" given their profitability, pipelines and valuations.
